SSRI and Buprenorphine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00475878
Recruitment Status : Completed
First Posted : May 21, 2007
Results First Posted : April 3, 2012
Last Update Posted : April 3, 2012
Information provided by (Responsible Party):
Michael Stein, MD, Butler Hospital

Brief Summary:
This study is designed to test whether treatment of depressive symptoms using escitalopram improves adherence to Buprenorphine and reduces symptoms of depression for individuals receiving Buprenorphine through their medical provider.

Condition or disease Intervention/treatment Phase
Opiate Dependence Depression Drug: escitalopram Drug: placebo Phase 3

Detailed Description:
Participants interested in receiving Buprenorphine will be offered the opportunity to enroll in this study. Enrolled study participants will complete interviews at baseline and again every two weeks for a total of 8 interviews over 3 months. In this double-blind randomized controlled trial, participants will either receive a placebo or escitalopram (10mg). All participants will also be followed by their Buprenorphine clinic medical provider. Questions during the face-to-face interviews will assess mood, drug craving, pain, sleep, medication adherence and drug-related experiences. Comparison(s): Participants randomized into the medication component of the study as compared to participants randomized into the placebo component of the study.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 147 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Antidepressants During Office-Based Buprenorphine
Study Start Date : December 2006
Actual Primary Completion Date : September 2009
Actual Study Completion Date : September 2009

Arm Intervention/treatment
Placebo Comparator: placebo Drug: placebo
placebo capsule/day for 3 months
Active Comparator: escitalopram Drug: escitalopram
10mg escitalopram/day for 3 months

Primary Outcome Measures :
  1. Percentage of Participants Who Dropped Out of Buprenorphine Treatment [ Time Frame: 3 months ]
    Drop-out is defined as 7 or more days of missed Buprenorphine doses

Secondary Outcome Measures :
  1. Depressive Symptoms [ Time Frame: 3 months ]
    Depressive symptoms, as measured by self-report during study interviews, using the Beck Depression Inventory II. Scores ranged from 0-63; higher scores indicate more depressive symptoms.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • opiate dependence
  • Ham-D > 14

Exclusion Criteria:

  • no psychiatric contraindications to using escitalopram
  • no medical contraindications to using escitalopram
  • methadone dose < 30
  • no current SSRI use

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00475878

United States, Rhode Island
Butler Hospital
Providence, Rhode Island, United States, 02906
Sponsors and Collaborators
Butler Hospital
Principal Investigator: Michael D Stein, M.D. Rhode Island Hospital

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Michael Stein, MD, Principal Investigator, Butler Hospital Identifier: NCT00475878     History of Changes
Other Study ID Numbers: DA022207
First Posted: May 21, 2007    Key Record Dates
Results First Posted: April 3, 2012
Last Update Posted: April 3, 2012
Last Verified: March 2012

Keywords provided by Michael Stein, MD, Butler Hospital:
opiate use

Additional relevant MeSH terms:
Opioid-Related Disorders
Behavioral Symptoms
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents